Astellas Pharma Inc (ALPMY)
9.86
-0.06
(-0.65%)
USD |
OTCM |
May 09, 11:56
Astellas Pharma Free Cash Flow (Quarterly): 244.52M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 244.52M |
| September 30, 2023 | 42.67M |
| June 30, 2023 | -30.35M |
| March 31, 2023 | 695.21M |
| December 31, 2022 | 351.30M |
| September 30, 2022 | 489.15M |
| June 30, 2022 | 235.95M |
| March 31, 2022 | 295.51M |
| December 31, 2021 | 485.34M |
| September 30, 2021 | 647.12M |
| June 30, 2021 | 184.28M |
| March 31, 2021 | 571.90M |
| December 31, 2020 | 914.45M |
| September 30, 2020 | 786.03M |
| June 30, 2020 | -108.37M |
| March 31, 2020 | 280.18M |
| December 31, 2019 | 399.86M |
| September 30, 2019 | 673.97M |
| June 30, 2019 | -28.08M |
| March 31, 2019 | 361.93M |
| December 31, 2018 | 665.59M |
| September 30, 2018 | 586.09M |
| June 30, 2018 | 249.06M |
| March 31, 2018 | 805.27M |
| December 31, 2017 | 756.09M |
| Date | Value |
|---|---|
| September 30, 2017 | 415.41M |
| June 30, 2017 | 481.11M |
| March 31, 2017 | 354.12M |
| December 31, 2016 | 701.49M |
| September 30, 2016 | 583.29M |
| June 30, 2016 | 89.98M |
| March 31, 2016 | 886.92M |
| December 31, 2015 | 147.73M |
| September 30, 2015 | 476.14M |
| June 30, 2015 | 119.39M |
| March 31, 2015 | 90.22M |
| December 31, 2014 | 167.74M |
| September 30, 2014 | 287.49M |
| June 30, 2014 | 428.63M |
| March 31, 2014 | 336.84M |
| December 31, 2013 | 601.41M |
| September 30, 2013 | 319.49M |
| June 30, 2013 | 320.88M |
| March 31, 2013 | |
| December 31, 2012 | |
| September 30, 2012 | |
| June 30, 2012 | |
| March 31, 2012 | |
| December 31, 2011 | |
| September 30, 2011 |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-108.37M
Minimum
Jun 2020
914.45M
Maximum
Dec 2020
375.30M
Average
351.30M
Median
Dec 2022
Free Cash Flow (Quarterly) Benchmarks
| Takeda Pharmaceutical Co Ltd | 476.74M |
| Nxera Pharma Co Ltd | -9.318M |
| PeptiDream Inc | 21.30M |
| Stemcell Holdings Inc | -- |
| Healios KK | -8.073M |